Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098960 | 0.95 | TP53 (0.50) | ALDH1A1FFAR4TP53NPSR1 | |
| SCHEMBL7101079 | 0.83 | TP53 (0.44) | ALDH1A1FFAR4TP53NPSR1 | |
| SCHEMBL7518536 | 0.79 | TP53 (0.41) | ALDH1A1FFAR4TP53MAPTNPSR1 | |
| SCHEMBL7513281 | 0.79 | HTR2C (0.47) | PGRALDH1A1MEN1HTTKMT2A | |
| SCHEMBL7512445 | 0.78 | ALDH1A1 (0.53) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL7518541 | 0.78 | ALDH1A1 (0.55) | ALDH1A1USP2TP53MAPTMEN1 | |
| SCHEMBL7517997 | 0.73 | S1PR1 (0.44) | PGRALDH1A1MAPTMEN1HTT | |
| SCHEMBL6465065 | 0.70 | TP53 (0.54) | KEAP1ALDH1A1USP2TP53MAPT | |
| SCHEMBL1629157 | 0.69 | KEAP1 (0.70) | KEAP1 | |
| SCHEMBL7522385 | 0.69 | S1PR1 (0.40) | PGRALDH1A1USP2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339668-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | claimed |
| WO-2002044126-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | PPIG, PIN1, PPIH | PGR 1977/4885KEAP1 1730/4885ALDH1A1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.